View source for Template:Relative affinities of levonorgestrel and metabolites

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Relative affinities of levonorgestrel and metabolites|mini=y}} Relative affinities (%) of levonorgestrel and metabolites
|-
! Compound || {{abbrlink|PR|Progesterone receptor}} || {{abbrlink|AR|Androgen receptor}} || {{abbrlink|ER|Estrogen receptor}} || {{abbrlink|GR|Glucocorticoid receptor}} || {{abbrlink|MR|Mineralocorticoid receptor}} || {{abbrlink|SHBG|Sex hormone-binding globulin}} || {{abbrlink|CBG|Corticosteroid binding globulin}}
|-
| {{No selflink|Levonorgestrel}} || 150–162 || 34<sup>a</sup>, 45 || 0 || 1–8 || 17–75 || 50 || 0
|-
| {{No selflink|5α-Dihydrolevonorgestrel}} || 50 || 38<sup>a</sup> || 0 || ? || ? || ? || ?
|-
| 3α,5α-Tetrahydrolevonorgestrel || ? || ? || 0.4 || ? || ? || ? || ?
|-
| 3β,5α-Tetrahydrolevonorgestrel || ? || ? || 2.4 || ? || ? || ? || ?
|- class="sortbottom"
| colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Notes:''' Values are percentages (%). Reference [[Biology:Ligand (biochemistry)|ligand]]s (100%) were [[Chemistry:Promegestone|promegestone f]]or the {{abbrlink|PR|progesterone receptor}}, [[Chemistry:Metribolone|metribolone (]]<sup>a</sup> = [[Chemistry:Mibolerone|mibolerone)]] for the {{abbrlink|AR|androgen receptor}}, [[Chemistry:Estradiol (medication)|{{abbr|E2|estradiol}}]] for the {{abbrlink|ER|estrogen receptor}}, {{abbrlink|DEXA|dexamethasone}} for the {{abbrlink|GR|glucocorticoid receptor}}, [[Chemistry:Aldosterone|aldosterone]] for the {{abbrlink|MR|mineralocorticoid receptor}}, {{abbrlink|DHT|dihydrotestosterone}} for {{abbrlink|SHBG|sex hormone-binding globulin}}, and [[Chemistry:Hydrocortisone|cortisol]] for {{abbrlink|CBG|Corticosteroid-binding globulin}}. '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue =  | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf | url-status = live | archiveurl = https://web.archive.org/web/20160822055012/http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf | archivedate = 2016-08-22 | df =  }}</ref><ref name="pmid10599548">{{cite journal | vauthors = Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M | title = The pharmacological profile of a novel norpregnance progestin (trimegestone) | journal = Gynecol. Endocrinol. | volume = 13 | issue = 5 | pages = 316–26 | date = October 1999 | pmid = 10599548 | doi = 10.3109/09513599909167574 | url = }}</ref><ref name="pmid11557270">{{cite journal | vauthors = Santillán R, Pérez-Palacios G, Reyes M, Damián-Matsumura P, García GA, Grillasca I, Lemus AE | title = Assessment of the oestrogenic activity of the contraceptive progestin levonorgestrel and its non-phenolic metabolites | journal = Eur. J. Pharmacol. | volume = 427 | issue = 2 | pages = 167–74 | date = September 2001 | pmid = 11557270 | doi = 10.1016/S0014-2999(01)01263-8 | url = }}</ref><ref name="pmid8545853">{{cite journal | vauthors = Cabeza M, Vilchis F, Lemus AE, Díaz de León L, Pérez-Palacios G | title = Molecular interactions of levonorgestrel and its 5 alpha-reduced derivative with androgen receptors in hamster flanking organs | journal = Steroids | volume = 60 | issue = 9 | pages = 630–5 | date = September 1995 | pmid = 8545853 | doi = 10.1016/0039-128X(95)00075-2 | url = }}</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>